Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3 | PharmaVoice

Pharma Tech

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Oct 30, 2026, 11:16 AM

Read Full Article → Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Translate article text

Choose a language and wait for the translated text.

Sales for Eli Lilly’s Mounjaro and Zepbound topped $16bn, exceeding total revenue for many big pharma players.